The present invention includes a composition and method for treating a glioblastoma in a human or animal subject comprising the steps of: identifying the human or animal subject in need of treatment of a glioblastoma, wherein the human or animal is no longer responsive to at least one of ...
Despite the progress in cancer treatment and the consequent improvement in survival rates, only modest advancements in the treatment of GBMs have occurred in the last decades. To overcome this picture, new therapeutic strategies against the highly proliferative activity of GBM cells have been studied...
With advances in genomic characterization of pediatric high-grade gliomas, the use of targeted therapies in combination with current treatment modalities offer the potential to improve survival in this patient population. In this report, we present the case of a 3-year-old girl with glioblastoma ...
CAR-T-cell therapy, a breakthrough in cancer treatment, has broadened the immunotherapy landscape [55]. However, antigen loss, immunoediting, and adaptive resistance are common phenomena that typically occur after CAR-T-cell therapy [66,231]. In addition, increased immunosuppression (e.g., upreg...
Their highly potent, inherently polyvalent oncolytic activity, coupled with intracavitary, local administration and a high safety profile, make them good candidates for the creation of safe combinatorial treatment regimens. Moreover, the new NK cell lines with higher expansion properties and with a ...
s TME in vivo. The future of GBM treatment depends on the development and utilisation of reproducible models incorporating all aspects of the TME to gain greater insights into the interconnectivity and subsequent treatment evasion mechanisms in GBM patients. With the development of new organoid models...
Patients with IDH-wild-type glioblastomas have a poor five-year survival rate along with limited treatment efficacy due to immune cell (glioma-associated microglia and macrophages) infiltration promoting tumour growth and resistance. To enhance therapeut
A new approach to treating the most malignant type of brain cancer - glioblastoma - has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates beyond 18 months. Targeted alpha therapy (TAT) is emerging as a potential additional treatment for glio...
Glioblastoma multiforme (GBM) is the most aggressive primary tumour within the brain as well as the most common and lethal cerebral cancer, mainly because of treatment failure. Indeed, tumour recurrence is inevitable and fatal in a short period of time. Glioblastoma stem-like cells (GSCs) are ...
Interstitial brachytherapy which requires the placement of radioactive isotopes (or seeds) into the surgical cavity is not an entirely new treatment, but due to continuing concerns such as radiation leakage into the surrounding brain, efforts into improving brachytherapy are underway, including the ...